-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
531 ，，。，2020270。、、，、、。TOP1080%，4，、。
270！、、
/、。，、、、，“”。
The number of diabetic patients in China currently ranks first in the world and is maintaining a growth trend.
Insulin occupies an important position in the treatment of diabetes, and its market size has continued to rise in recent years.
According to data from Menet.
com, in 2020, the sales of terminal insulin and similar drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 27 billion yuan, a year-on-year increase of 7.
91%.
Insulin occupies an important position in the treatment of diabetes, and its market size has continued to rise in recent years.
According to data from Menet.
com, in 2020, the sales of terminal insulin and similar drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 27 billion yuan, a year-on-year increase of 7.
91%.
Sales of terminal insulin and similar drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Due to the high technical barriers to insulin products, the three foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied the dominant position in the domestic insulin market.
Domestic pharmaceutical companies Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
In 2020, the total market share of the three major foreign companies will still exceed 70%, but the market share of Novo Nordisk and Eli Lilly has declined compared with 2019.
Domestic pharmaceutical companies Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
In 2020, the total market share of the three major foreign companies will still exceed 70%, but the market share of Novo Nordisk and Eli Lilly has declined compared with 2019.
It is worth mentioning that in recent years, Ganli Pharmaceutical's insulin product sales have continued to rise, and the market share has also continued to expand.
In 2020, it has successfully exceeded 10% and is expected to surpass Eli Lilly and break into the top three in the future.
In 2020, it has successfully exceeded 10% and is expected to surpass Eli Lilly and break into the top three in the future.
Market share of TOP5 manufacturers of terminal insulin and similar drugs in China's public medical institutions
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
TOP10 brands rose across the board! Gan Li, Tonghua Dongbao, and the Federation are on the list
2020 Chinese public medical institutions terminal similar to insulin and its pharmaceutical brand TOP10
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Among the TOP10 brands of insulin and similar drugs, the sales of 10 brands have achieved varying degrees of growth, with a total market share of more than 80%.
Novo Nordisk has as many as 4 brands on the list, Eli Lilly and Sanofi have 2 and 1 brands respectively, and Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories have 1 brands on the list.
Novo Nordisk has as many as 4 brands on the list, Eli Lilly and Sanofi have 2 and 1 brands respectively, and Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories have 1 brands on the list.
Sales of the two brands increased strongly.
United Laboratories' protamine recombinant human insulin mixed injection (30/70) sales increased by 21.
65%, and Ganli Pharmaceutical's recombinant insulin glargine injection increased by 15.
46%.
United Laboratories' protamine recombinant human insulin mixed injection (30/70) sales increased by 21.
65%, and Ganli Pharmaceutical's recombinant insulin glargine injection increased by 15.
46%.
There are 8 brands with sales of more than 1 billion yuan.
Novo Nordisk's insulin aspart 30 injection ranked first with sales of more than 5 billion yuan; Sanofi's insulin glargine injection, Novo Nordisk The protamine recombinant human insulin mixed injection (30R) ranked second and third respectively, with sales exceeding 4 billion yuan and 3 billion yuan respectively.
Novo Nordisk's insulin aspart 30 injection ranked first with sales of more than 5 billion yuan; Sanofi's insulin glargine injection, Novo Nordisk The protamine recombinant human insulin mixed injection (30R) ranked second and third respectively, with sales exceeding 4 billion yuan and 3 billion yuan respectively.
6 major domestic new products are coming! Gan Li, Tonghua Dongbao, Dongyang Pharmaceutical.
.
.
.
.
Since 2019, although there are only a handful of insulin products approved for listing in the domestic market, they are quite bright.
In terms of imported products, Novo Nordisk's Degu aspart insulin injection (Novoga) and Sanofi's insulin glargine injection (Laiyoushi) were approved for import in 2019 and 2020, respectively.
Among them, Novoga is a soluble preparation consisting of basal insulin (Degu) and prandial insulin (aspart).
It is the world's first soluble dual insulin and fills the gap in the domestic market.
Among them, Novoga is a soluble preparation consisting of basal insulin (Degu) and prandial insulin (aspart).
It is the world's first soluble dual insulin and fills the gap in the domestic market.
In terms of domestic products, a total of 6 insulin products have been approved for listing by local companies since 2019 , including 4 companies including Dongyang Sun Pharmaceutical, Hefei Tianmai, Tonghua Dongbao, Ganli Pharmaceutical, and Ganli Pharmaceutical alone has won three products.
Among them, Dongyang Pharmaceutical’s recombinant human insulin injection is the company’s first insulin product; Tonghua Dongbao’s insulin glargine injection is the third domestically produced and the company’s first third-generation insulin product.
Among them, Dongyang Pharmaceutical’s recombinant human insulin injection is the company’s first insulin product; Tonghua Dongbao’s insulin glargine injection is the third domestically produced and the company’s first third-generation insulin product.
Since 2019, local companies have been approved for insulin products
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In 2020, Ganli Pharmaceutical's insulin aspart injection and insulin aspart 30 injection were successively approved for marketing, both of which are third-generation insulins.
On May 24, 2021, Ganli Pharmaceutical's protamine recombinant human insulin injection (premixed 30R) was approved for listing, becoming the company's first second-generation insulin product.
This product is a premixed insulin composed of 30% soluble human insulin and 70% protamine human insulin.
Up to now, Ganli Pharmaceutical has approved 5 third-generation insulins and 1 second-generation insulin for listing.
On May 24, 2021, Ganli Pharmaceutical's protamine recombinant human insulin injection (premixed 30R) was approved for listing, becoming the company's first second-generation insulin product.
This product is a premixed insulin composed of 30% soluble human insulin and 70% protamine human insulin.
Up to now, Ganli Pharmaceutical has approved 5 third-generation insulins and 1 second-generation insulin for listing.
Data source: Mi Neiwang database
Medical Network News on May 31 A few days ago, Ganli Pharmaceutical's first second-generation insulin was approved for listing, and its leading position has been consolidated.
In recent years, the domestic market for insulin and its similar drugs has continued to rise.
In 2020, the terminal sales of public medical institutions in China will be close to 27 billion yuan.
The three major foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied a dominant position, while the three domestic pharmaceutical companies of Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
The total market share of TOP10 brands exceeds 80%.
Novo Nordisk has as many as 4 brands on the list.
The sales of Ganli Pharmaceutical and United Laboratories on the list have grown strongly.
In recent years, the domestic market for insulin and its similar drugs has continued to rise.
In 2020, the terminal sales of public medical institutions in China will be close to 27 billion yuan.
The three major foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied a dominant position, while the three domestic pharmaceutical companies of Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
The total market share of TOP10 brands exceeds 80%.
Novo Nordisk has as many as 4 brands on the list.
The sales of Ganli Pharmaceutical and United Laboratories on the list have grown strongly.
27 billion insulin market! Novo Nordisk, Sanofi and Eli Lilly are among the top three
Diabetes is a due to the defects in insulin secretion and / or biological action due to obstacles to blood sugar-based integrated metabolism disorders .
Clinically, hyperglycemia is the main feature, and typical cases may have symptoms such as polyuria, polydipsia, polyphagia, weight loss, etc.
, that is, "three more and one less" symptoms.
Clinically, hyperglycemia is the main feature, and typical cases may have symptoms such as polyuria, polydipsia, polyphagia, weight loss, etc.
, that is, "three more and one less" symptoms.
The number of diabetic patients in China currently ranks first in the world and is maintaining a growth trend.
Insulin occupies an important position in the treatment of diabetes, and its market size has continued to rise in recent years.
According to data from Menet.
com, in 2020, the sales of terminal insulin and similar drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 27 billion yuan, a year-on-year increase of 7.
91%.
Insulin occupies an important position in the treatment of diabetes, and its market size has continued to rise in recent years.
According to data from Menet.
com, in 2020, the sales of terminal insulin and similar drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 27 billion yuan, a year-on-year increase of 7.
91%.
Sales of terminal insulin and similar drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Due to the high technical barriers to insulin products, the three foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied the dominant position in the domestic insulin market.
Domestic pharmaceutical companies Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
In 2020, the total market share of the three major foreign companies will still exceed 70%, but the market share of Novo Nordisk and Eli Lilly has declined compared with 2019.
Domestic pharmaceutical companies Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
In 2020, the total market share of the three major foreign companies will still exceed 70%, but the market share of Novo Nordisk and Eli Lilly has declined compared with 2019.
It is worth mentioning that in recent years, Ganli Pharmaceutical's insulin product sales have continued to rise, and the market share has also continued to expand.
In 2020, it has successfully exceeded 10% and is expected to surpass Eli Lilly and break into the top three in the future.
In 2020, it has successfully exceeded 10% and is expected to surpass Eli Lilly and break into the top three in the future.
Market share of TOP5 manufacturers of terminal insulin and similar drugs in China's public medical institutions
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
TOP10 brands rose across the board! Gan Li, Tonghua Dongbao, and the Federation are on the list
2020 Chinese public medical institutions terminal similar to insulin and its pharmaceutical brand TOP10
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Among the TOP10 brands of insulin and similar drugs, the sales of 10 brands have achieved varying degrees of growth, with a total market share of more than 80%.
Novo Nordisk has as many as 4 brands on the list, Eli Lilly and Sanofi have 2 and 1 brands respectively, and Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories have 1 brands on the list.
Novo Nordisk has as many as 4 brands on the list, Eli Lilly and Sanofi have 2 and 1 brands respectively, and Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories have 1 brands on the list.
Sales of the two brands increased strongly.
United Laboratories' protamine recombinant human insulin mixed injection (30/70) sales increased by 21.
65%, and Ganli Pharmaceutical's recombinant insulin glargine injection increased by 15.
46%.
United Laboratories' protamine recombinant human insulin mixed injection (30/70) sales increased by 21.
65%, and Ganli Pharmaceutical's recombinant insulin glargine injection increased by 15.
46%.
There are 8 brands with sales of more than 1 billion yuan.
Novo Nordisk's insulin aspart 30 injection ranked first with sales of more than 5 billion yuan; Sanofi's insulin glargine injection, Novo Nordisk The protamine recombinant human insulin mixed injection (30R) ranked second and third respectively, with sales exceeding 4 billion yuan and 3 billion yuan respectively.
Novo Nordisk's insulin aspart 30 injection ranked first with sales of more than 5 billion yuan; Sanofi's insulin glargine injection, Novo Nordisk The protamine recombinant human insulin mixed injection (30R) ranked second and third respectively, with sales exceeding 4 billion yuan and 3 billion yuan respectively.
6 major domestic new products are coming! Gan Li, Tonghua Dongbao, Dongyang Pharmaceutical.
.
.
.
.
Since 2019, although there are only a handful of insulin products approved for listing in the domestic market, they are quite bright.
In terms of imported products, Novo Nordisk's Degu aspart insulin injection (Novoga) and Sanofi's insulin glargine injection (Laiyoushi) were approved for import in 2019 and 2020, respectively.
Among them, Novoga is a soluble preparation consisting of basal insulin (Degu) and prandial insulin (aspart).
It is the world's first soluble dual insulin and fills the gap in the domestic market.
Among them, Novoga is a soluble preparation consisting of basal insulin (Degu) and prandial insulin (aspart).
It is the world's first soluble dual insulin and fills the gap in the domestic market.
In terms of domestic products, a total of 6 insulin products have been approved for listing by local companies since 2019 , including 4 companies including Dongyang Sun Pharmaceutical, Hefei Tianmai, Tonghua Dongbao, Ganli Pharmaceutical, and Ganli Pharmaceutical alone has won three products.
Among them, Dongyang Pharmaceutical’s recombinant human insulin injection is the company’s first insulin product; Tonghua Dongbao’s insulin glargine injection is the third domestically produced and the company’s first third-generation insulin product.
Among them, Dongyang Pharmaceutical’s recombinant human insulin injection is the company’s first insulin product; Tonghua Dongbao’s insulin glargine injection is the third domestically produced and the company’s first third-generation insulin product.
Since 2019, local companies have been approved for insulin products
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In 2020, Ganli Pharmaceutical's insulin aspart injection and insulin aspart 30 injection were successively approved for marketing, both of which are third-generation insulins.
On May 24, 2021, Ganli Pharmaceutical's protamine recombinant human insulin injection (premixed 30R) was approved for listing, becoming the company's first second-generation insulin product.
This product is a premixed insulin composed of 30% soluble human insulin and 70% protamine human insulin.
Up to now, Ganli Pharmaceutical has approved 5 third-generation insulins and 1 second-generation insulin for listing.
On May 24, 2021, Ganli Pharmaceutical's protamine recombinant human insulin injection (premixed 30R) was approved for listing, becoming the company's first second-generation insulin product.
This product is a premixed insulin composed of 30% soluble human insulin and 70% protamine human insulin.
Up to now, Ganli Pharmaceutical has approved 5 third-generation insulins and 1 second-generation insulin for listing.
Data source: Mi Neiwang database
Medical Network News on May 31 A few days ago, Ganli Pharmaceutical's first second-generation insulin was approved for listing, and its leading position has been consolidated.
In recent years, the domestic market for insulin and its similar drugs has continued to rise.
In 2020, the terminal sales of public medical institutions in China will be close to 27 billion yuan.
The three major foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied a dominant position, while the three domestic pharmaceutical companies of Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
The total market share of TOP10 brands exceeds 80%.
Novo Nordisk has as many as 4 brands on the list.
The sales of Ganli Pharmaceutical and United Laboratories on the list have grown strongly.
In recent years, the domestic market for insulin and its similar drugs has continued to rise.
In 2020, the terminal sales of public medical institutions in China will be close to 27 billion yuan.
The three major foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied a dominant position, while the three domestic pharmaceutical companies of Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
The total market share of TOP10 brands exceeds 80%.
Novo Nordisk has as many as 4 brands on the list.
The sales of Ganli Pharmaceutical and United Laboratories on the list have grown strongly.
27 billion insulin market! Novo Nordisk, Sanofi and Eli Lilly are among the top three
27 billion insulin market! Novo Nordisk, Sanofi and Eli Lilly are among the top three Diabetes is a due to the defects in insulin secretion and / or biological action due to obstacles to blood sugar-based integrated metabolism disorders .
Clinically, hyperglycemia is the main feature, and typical cases may have symptoms such as polyuria, polydipsia, polyphagia, weight loss, etc.
, that is, "three more and one less" symptoms.
Disease disease diseaseClinically, hyperglycemia is the main feature, and typical cases may have symptoms such as polyuria, polydipsia, polyphagia, weight loss, etc.
, that is, "three more and one less" symptoms.
The number of diabetic patients in China currently ranks first in the world and is maintaining a growth trend.
Insulin occupies an important position in the treatment of diabetes, and its market size has continued to rise in recent years.
According to data from Menet.
com, in 2020, the sales of terminal insulin and similar drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 27 billion yuan, a year-on-year increase of 7.
91%.
Hospital hospital hospitalInsulin occupies an important position in the treatment of diabetes, and its market size has continued to rise in recent years.
According to data from Menet.
com, in 2020, the sales of terminal insulin and similar drugs in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) will be close to 27 billion yuan, a year-on-year increase of 7.
91%.
Sales of terminal insulin and similar drugs in public medical institutions in China (unit: ten thousand yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Due to the high technical barriers to insulin products, the three foreign companies, Novo Nordisk, Sanofi, and Eli Lilly, have long occupied the dominant position in the domestic insulin market.
Domestic pharmaceutical companies Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
In 2020, the total market share of the three major foreign companies will still exceed 70%, but the market share of Novo Nordisk and Eli Lilly has declined compared with 2019.
Domestic pharmaceutical companies Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories are struggling to catch up.
In 2020, the total market share of the three major foreign companies will still exceed 70%, but the market share of Novo Nordisk and Eli Lilly has declined compared with 2019.
It is worth mentioning that in recent years, Ganli Pharmaceutical's insulin product sales have continued to rise, and the market share has also continued to expand.
In 2020, it has successfully exceeded 10% and is expected to surpass Eli Lilly and break into the top three in the future.
In 2020, it has successfully exceeded 10% and is expected to surpass Eli Lilly and break into the top three in the future.
Market share of TOP5 manufacturers of terminal insulin and similar drugs in China's public medical institutions
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
TOP10 brands rose across the board! Gan Li, Tonghua Dongbao, and the Federation are on the list
TOP10 brands rose across the board! Gan Li, Tonghua Dongbao, and the Federation are on the list 2020 Chinese public medical institutions terminal similar to insulin and its pharmaceutical brand TOP10
Medicine, medicine, medicine Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
Among the TOP10 brands of insulin and similar drugs, the sales of 10 brands have achieved varying degrees of growth, with a total market share of more than 80%.
Novo Nordisk has as many as 4 brands on the list, Eli Lilly and Sanofi have 2 and 1 brands respectively, and Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories have 1 brands on the list.
Novo Nordisk has as many as 4 brands on the list, Eli Lilly and Sanofi have 2 and 1 brands respectively, and Ganli Pharmaceutical, Tonghua Dongbao, and United Laboratories have 1 brands on the list.
Sales of the two brands increased strongly.
United Laboratories' protamine recombinant human insulin mixed injection (30/70) sales increased by 21.
65%, and Ganli Pharmaceutical's recombinant insulin glargine injection increased by 15.
46%.
United Laboratories' protamine recombinant human insulin mixed injection (30/70) sales increased by 21.
65%, and Ganli Pharmaceutical's recombinant insulin glargine injection increased by 15.
46%.
There are 8 brands with sales of more than 1 billion yuan.
Novo Nordisk's insulin aspart 30 injection ranked first with sales of more than 5 billion yuan; Sanofi's insulin glargine injection, Novo Nordisk The protamine recombinant human insulin mixed injection (30R) ranked second and third respectively, with sales exceeding 4 billion yuan and 3 billion yuan respectively.
Novo Nordisk's insulin aspart 30 injection ranked first with sales of more than 5 billion yuan; Sanofi's insulin glargine injection, Novo Nordisk The protamine recombinant human insulin mixed injection (30R) ranked second and third respectively, with sales exceeding 4 billion yuan and 3 billion yuan respectively.
6 major domestic new products are coming! Gan Li, Tonghua Dongbao, Dongyang Pharmaceutical.
.
.
6 major domestic new products are coming! Gan Li, Tonghua Dongbao, Dongyang Pharmaceutical. .
.
.
.
Since 2019, although there are only a handful of insulin products approved for listing in the domestic market, they are quite bright.
In terms of imported products, Novo Nordisk's Degu aspart insulin injection (Novoga) and Sanofi's insulin glargine injection (Laiyoushi) were approved for import in 2019 and 2020, respectively.
Among them, Novoga is a soluble preparation consisting of basal insulin (Degu) and prandial insulin (aspart).
It is the world's first soluble dual insulin and fills the gap in the domestic market.
Among them, Novoga is a soluble preparation consisting of basal insulin (Degu) and prandial insulin (aspart).
It is the world's first soluble dual insulin and fills the gap in the domestic market.
In terms of domestic products, a total of 6 insulin products have been approved for listing by local companies since 2019 , including 4 companies including Dongyang Sun Pharmaceutical, Hefei Tianmai, Tonghua Dongbao, Ganli Pharmaceutical, and Ganli Pharmaceutical alone has won three products.
Among them, Dongyang Pharmaceutical’s recombinant human insulin injection is the company’s first insulin product; Tonghua Dongbao’s insulin glargine injection is the third domestically produced and the company’s first third-generation insulin product.
Enterprise business enterpriseAmong them, Dongyang Pharmaceutical’s recombinant human insulin injection is the company’s first insulin product; Tonghua Dongbao’s insulin glargine injection is the third domestically produced and the company’s first third-generation insulin product.
Since 2019, local companies have been approved for insulin products
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In 2020, Ganli Pharmaceutical's insulin aspart injection and insulin aspart 30 injection were successively approved for marketing, both of which are third-generation insulins.
On May 24, 2021, Ganli Pharmaceutical's protamine recombinant human insulin injection (premixed 30R) was approved for listing, becoming the company's first second-generation insulin product.
This product is a premixed insulin composed of 30% soluble human insulin and 70% protamine human insulin.
Up to now, Ganli Pharmaceutical has approved 5 third-generation insulins and 1 second-generation insulin for listing.
On May 24, 2021, Ganli Pharmaceutical's protamine recombinant human insulin injection (premixed 30R) was approved for listing, becoming the company's first second-generation insulin product.
This product is a premixed insulin composed of 30% soluble human insulin and 70% protamine human insulin.
Up to now, Ganli Pharmaceutical has approved 5 third-generation insulins and 1 second-generation insulin for listing.
Data source: Mi Neiwang database
